ALK-Rearranged Non-Small Cell Lung Cancer Clinical Trial
Official title:
A Phase I/II Study of the ALK Inhibitor CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer
CH5424802 is a newly invented, selective oral ALK inhibitor. In the Phase I portion, the goal is to determine the following: dose limiting toxicity, the maximum tolerated dose, pharmacokinetic (PK) parameters, and the recommended dose.
n/a
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment